Avicanna to Buy Medical Cannabis by Shoppers Business
Provided by
Dow Jones
By Robb M. Stewart
Biopharmaceutical company Avicanna said Monday that it has struck a definitive deal to buy the medical cannabis assets of pharmacy chain Shoppers Drug Mart for roughly 2.6 million Canadian dollars ($1.9 million).
Under the agreement, Avicanna will pay Shoppers an earn-out fee based on net revenue for a period of two years. The purchase includes specific assets, inventory and equipment.
The deal is set to close July 31, Avicanna said.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
May 29, 2023 08:06 ET (12:06 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now
-
Paramount Earnings: CEO Has Gone, For-Sale Sign Is Up; Good Results Would’ve Been Nice to Learn
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?